Episode 1 – Biosimilars: what are they, and why might they be important for MS?
01 września 2025
In the very first episode of the Illuminoz podcast series, Bianca Stadler, Regional Medical Lead at Sandoz, sits down with Dr. Wallace Brownlee, neurologist at the Queen Square MS Centre in London, to explore the world of biosimilars and their role in multiple sclerosis treatment.
What exactly are biosimilars, and how do they differ from generics? What does the approval process look like? And how can these therapies help expand access to care while reducing healthcare costs?
Tune in to discover how biosimilars are reshaping the MS treatment landscape—and why neurology may be the next frontier for broader adoption.
Informacje o podcaście:
“Illuminoz talks 2025” podcast series:
Episode 12 – PML: what is it, and why is it relevant in MS?
dr Tobias Bopp,
Episode 11 – Introducing biosimilar natalizumab
dr Heinz Wiendl,
Episode 10 – Patient conversations part three: the patient perspective
Ellen Tutton,
Episode 9 – Patient conversations part two: the nurse perspective
karolinamalicka,
Episode 8 – Patient conversations part one: the neurologist perspective
dr Agne Straukiene,
Episode 7 – Lessons learned part two: the value of biosimilars in rheumatology
prof. Paul Emery,
Episode 6 – Lessons learned part one: the value of biosimilars in oncology
prof. Kai Hübel,
Episode 5 – Biosimilars and MS: improving access to high-efficacy treatment
dr Barbara Kornek,
Episode 4 – Treatment paradigms in MS: right patient, right treatment, right time
dr Laura Airas,
Episode 3 – MS treatment landscape part two: potential role of biosimilars
dr David Paling,
Episode 2 – MS treatment landscape part one: unmet needs
dr Luisa Klotz,
